Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...
Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of ...
Edmonton Journal on MSN
Two Alberta supervised consumption sites shut down in 2025 with plans to close Calgary's in the new year
Alberta closed two supervised consumption sites in 2025 with plans to close a third in 2026. The supervised consumption site ...
Read honest MedVI Weight Loss reviews covering GLP-1 medication, benefits, pricing, side effects, and real user results.
An update from Sisram Medical Ltd. ( ($HK:1696) ) is now available. Sisram Medical has announced that its sublicensed botulinum toxin type A ...
GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...
ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection ...
Micro injection molding has become a cornerstone for mass-producing microfluidic devices, yet demolding defects and mold wear remain persistent challenges. This study introduces a nickel mold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback